Dexcom announced that its Dexcom G7 15 Day continuous glucose monitoring (CGM) system for adults will launch in the U.S. on December 1.

At first launch, Dexcom G7 15 Day will become available for users who receive their Dexcom CGM through DME providers. It will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic systems set forth by the U.S. Centers for Medicare & Medicaid Services (CMS).

Dexcom G7 15 Day has an overall MARD of 8% and can be worn for 15.5 days. It allows easier glucose management with fewer monthly sensor changes and reduced monthly waste, the company said.

“We’ve heard loud and clear from our users—they want more time with the Dexcom G7 because it gives them confidence, clarity, and control over their health,” said Grant Ovzinsky, VP of product management at Dexcom. “With 15.5 days of wear, we’re delivering on that ask. Fewer sensor changes mean less disruption, and more time benefiting from the most accurate CGM. It’s a meaningful step forward in empowering people with diabetes to live life on their terms.”

At launch, it will connect with the iLet Bionic Pancreas and Omnipod 5 insulin pumps. The company said it’s working with Tandem Diabetes and plans to extend the launch to their customers as they finalize integration.

“As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” said David Padilla, a Dexcom Warrior. “The new Dexcom G7 15 Day CGM System is going to give me, and so many others like me, more time to focus on what really matters while diabetes takes a backseat.”

Yesterday, the company revealed it had obtained U.S. Food and Drug Administration for Smart Basal, a CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.